REPUBLIC OF KENYA

MINISTRY OF HEALTH

PHARMACY AND POISONS BOARD

PUBLIC ALERT

FALSIFIED IBRANCE (PALBOCICLIB), BATCH NO. FS5173, GS4328, LV1850, TS2190, GK2981, GR6491, GT5817, HJ8710, and HJ8715

The Pharmacy and Poisons Board ("the Board") is mandated by Cap 244 of the Laws of Kenya to protect and promote public health by regulating the pharmacy profession and ensuring access to quality, safe, and effective health products and technologies ("HPTs").

In furtherance of this mandate, the Board undertakes post-marketing surveillance activities to monitor HPTs circulating in the market and to take appropriate regulatory actions in safeguarding public health.

During the course of these surveillance activities, **the Board received an alert from the World Health Organization (WHO) regarding falsified IBRANCE® (palbociclib).** According to the alert, nine falsified lots of the product have been identified in various countries.

The confirmed falsified batch numbers are as follows: **FS5173, GS4328, LV1850,** and **TS2190**. In addition, the following batch numbers are considered suspicious and likely to be falsified: **GK2981, GR6491, GT5817, HJ8710, and HJ8715**.

The falsified products claim to have been manufactured by **Pfizer, P.O. Box 29387, Mission, KS 66201.** The reported falsification features include:

1. Labels with spelling errors or poor-quality printing.
2. Security foil on the bottle displaying the Pfizer logo printed in black ink.
3. Capsules marked with "PBC 125" in black ink or lacking any markings.
4. Capsules are an unusual color (e.g., bright orange).

Laboratory analysis has confirmed that the falsified products do not contain any Active Pharmaceutical Ingredient. These products are therefore unsafe for use and pose a serious risk to patient safety and public health.

PUBLIC ADVISORY

To date, the Board has not detected or confirmed the presence of the above falsified batches of IBRANCE within the Kenyan market. This alert is therefore issued as a **precautionary measure** to enhance vigilance, prevent potential entry into the supply chain, and safeguard public health. In light of the above, the Board advises as follows:

1. Procurement agencies, hospitals, distributors, pharmacists, pharmaceutical technologists, and members of the public are urged **to remain vigilant and report immediately any encounter with the falsified product batches.**
2. All stakeholders within the supply chain to procure HPTs exclusively from licensed manufacturers, importers, distributors, and retailers. Procuring from unlicensed sources endangers patients and constitutes a violation of the Pharmacy and Poisons Act, Cap 244 of the Laws of Kenya.

The Board, together with relevant Government investigative agencies, will take firm regulatory and legal action against any individual or entity involved in the distribution of this and any other falsified batches of HPTs.

HOW TO REPORT

Any suspected falsified or substandard medicine, should be reported through the following official channels:

- Online portal: https://pv.pharmacyboardkenya.org/users/mpublic
- USSD Code: *271#
- Mobile App: mPvERS (Android & iOS)
- Email: pv@ppb.go.ke | pms@ppb.go.ke
- Telephone: 0795743049

The Pharmacy and Poisons Board remains committed to protecting and safeguarding public health. Your cooperation is essential in ensuring the quality, safety and efficacy of Health Products and Technologies in Kenya.

Dr. Ahmed I. Mohamed
Ag. CHIEF EXECUTIVE OFFICER
24th December 2025

PRODUCT PHOTO

Lot: FS5173	Lot: FS5173	Lot: GR6491	Lot: HJ8710	Lot: GT5817	Lot: LV1850
Lebanon	Côte d'Ivoire	Türkiye	Egypt	Egypt	Libya